Governance Positive

2026-05-22 19:03

Isera Lifesciences Limited's shareholders have approved all seven resolutions through a postal ballot, as confirmed by the Scrutinizer's Report dated May 22, 2026. Key approvals include an increase in authorised share capital, adoption of new Memorandum and Articles of Association, enhanced limits for investments and guarantees, and the acquisition of up to 100% equity shareholding of ISERA Biological Limited via share swap. Shareholders also approved the issuance of equity shares through a preferential issue for the share swap.

Governance Neutral

2026-05-21 20:10

CRITICAL RED FLAG DETECTED

ISERA Lifesciences Limited's Board meeting on May 21, 2026, approved standalone audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The company reported no cash losses in the last two financial years and successfully completed a Rights Issue worth ₹8.08 crore. A statutory auditor resignation occurred during the year, but no concerns were raised by the outgoing auditors.

Financials Negative

2026-05-21 20:06

CRITICAL RED FLAG DETECTED

The Board of Directors of ISERA Lifesciences Limited approved the Audited Standalone Financial Results for the quarter and year ended March 31, 2026, during a meeting on May 21, 2026. The Independent Auditor, GMKS & Co., issued an unmodified opinion on these financial statements. However, the filing also notes that there was a resignation of the statutory auditors of the Company during the year.

Financials Negative

2026-05-21 19:58

CRITICAL RED FLAG DETECTED

The Board of Directors of ISERA Lifesciences Limited met on May 21, 2026, and approved the Audited Standalone Financial Results for the quarter and year ended March 31, 2026. The company also filed the Independent Auditor's Report, which expressed an unmodified opinion. It was noted that the statutory auditors had resigned during the year, though without raising any issues or concerns.

Financials Neutral

2026-05-15 12:43

iSERA Lifesciences Limited announced that a Board Meeting will be held on Thursday, May 21, 2026, to consider, approve, and take on record the Standalone Audited Financial Results for the quarter and year ended March 31, 2026. The trading window for designated persons remains closed from April 01, 2026, until 48 hours after the declaration of the results.

Governance Positive

2026-04-21 18:29

iSERA Lifesciences Limited has issued a Postal Ballot Notice seeking shareholder approval for several key resolutions, including increasing its Authorised Share Capital, adopting new MOA/AOA, enhancing limits for investments/loans/guarantees, and the acquisition of iSERA Biological Limited via share swap. E-voting is from April 22 to May 21, 2026.

Governance Positive

2026-04-21 15:31

Board meeting on April 21, 2026, approved increasing Authorised Share Capital to ₹25 Cr. Key approvals include acquiring 100% equity of iSERA Biological Limited for ₹78 Cr via a 1:1 share swap, making it a Wholly Owned Subsidiary, and enhancing investment limits to ₹1000 Cr.

Governance Positive

2026-04-21 13:15

Board approved increasing authorized share capital from ₹11Cr to ₹25Cr and enhancing Section 186 limits to ₹1,000Cr. They also approved acquiring 100% of ISERA Biological Limited for ₹78Cr via a 1:1 share swap at ₹48.20/share, making it a Wholly Owned Subsidiary, subject to shareholder approval.

Business Update Positive

2026-04-21 13:13

The Board approved increasing authorized share capital to ₹25Cr and investment limits to ₹1,000Cr. It also approved the acquisition of up to 100% equity of ISERA Biological Limited, a related party, for ₹78Cr via a 1:1 share swap, making it a Wholly Owned Subsidiary, pending members' approval.

Business Update Positive

2026-04-21 13:12

The Board approved increasing Authorized Share Capital to ₹25Cr, adopting new MOA/AOA, and enhancing investment limits to ₹1,000Cr. Crucially, it approved acquiring up to 100% equity of ISERA Biological Limited for ₹78.00Cr via a 1:1 share swap (1.61Cr shares at ₹48.20/share), making it a Wholly Owned Subsidiary.

Governance Positive

2026-04-21 13:11

Board approved increasing authorized share capital from ₹11Cr to ₹25Cr and enhancing investment limits up to ₹1,000Cr. It also approved acquiring 100% equity of ISERA Biological Limited for ₹78.00Cr via a share swap, making it a wholly-owned subsidiary. Decisions are subject to shareholder approval via postal ballot.

Governance Positive

2026-04-21 13:07

Board meeting on April 21, 2026, approved increasing Authorised Share Capital from ₹11 Cr to ₹25 Cr. The Board also approved the acquisition of 100% equity of iSERA Biological Limited (a related party) for ₹78.00 Cr via a 1:1 share swap at ₹48.20/share, making it a wholly-owned subsidiary. Additionally, new MOA/AOA and enhanced Section 186 limits were approved.

Governance Neutral

2026-04-20 17:03

iSERA Lifesciences Limited has deferred its Board Meeting scheduled for April 20, 2026, which was to consider a preferential issue of equity shares. The deferment is due to the requirement of additional time for procedural and documentation-related formalities.

Governance Positive

2026-04-15 17:47

ISERA Lifesciences Limited announced a Board Meeting on April 20, 2026, to consider and approve a preferential issue of equity shares on a private placement basis.

Routine Neutral

2026-04-10 17:53

New Filing detected. See link for details.

Governance Positive

2026-04-03 17:09

Covidh Technologies Limited held its 01st EGM on April 2, 2026. All 5 resolutions passed, including the change of company name to iSERA LIFESCIENCES LIMITED and the appointment of Mr. Dhairyasheel Vasantrao Yadav and Mr. Nandkumar Subhash Kadam as Executive Directors.

Governance Positive

2026-04-02 13:29

An Extra-Ordinary General Meeting was held on April 02, 2026. Members approved changing the company name from Covidh Technologies Limited to iSERA Lifesciences Limited. The appointment of two Executive Directors and two Non-Executive, Non-Independent Directors was also approved.

Governance Neutral

2026-04-02 13:26

Covidh Technologies Limited held an EGM on April 02, 2026. Shareholders approved changing the company's name to iSERA Lifesciences Limited. Additionally, new Executive Directors (Mr. Dhairyasheel Yadav, Mr. Nandkumar Kadam) and Non-Executive, Non-Independent Directors (Mr. Pratap Deshmukh, Ms. Ritu Garad) were appointed.

Routine Neutral

2026-03-27 16:54

COVIDH TECHNOLOGIES LIMITED announced the closure of its trading window for designated persons from April 01, 2026, until 48 hours after the Audited Financial Results for the Quarter ended March 31, 2026, are made public, to prevent insider trading. The Board Meeting date for results will be intimated later.

Governance Neutral

2026-03-11 15:30

Covidh Technologies Limited will hold an EGM on April 2, 2026, to approve changing the company name to iSERA Lifesciences Limited and the appointment of two Executive Directors (Mr. Yadav, Mr. Kadam) and two Non-Executive Non-Independent Directors (Mr. Deshmukh, Ms. Garad) for five years.

Governance Positive

2026-03-10 16:16

The Board of Directors of Covidh Technologies Limited, on March 10, 2026, approved changing the company name to iSERA Lifesciences Limited, shifting its registered office, and recommending the appointment of four new directors (two Executive, two Non-Executive). An EGM will be held on April 2, 2026, for shareholder approvals.

Governance Neutral

2026-03-10 15:46

Covidh Technologies Board met on March 10, 2026, approving name change to 'iSERA Lifesciences Limited' and shifting registered office. It also recommended appointing two Executive and two Non-Executive Directors. An EGM is scheduled for April 2, 2026, to seek shareholder approvals.

Governance Positive

2026-03-10 15:38

Covidh Technologies Limited's Board meeting on March 10, 2026, approved changing the company name to iSERA Lifesciences Limited, shifting its registered office, and recommending the appointment of two Executive Directors and two Non-Executive Directors for 5-year terms, subject to EGM approval on April 2, 2026.

Governance Positive

2026-03-10 15:31

Board approved changing the company name to iSERA Lifesciences Limited and shifting the registered office. It also recommended appointing Mr. Dhairyasheel Yadav and Mr. Nandkumar Kadam as Executive Directors, and Mr. Pratap Deshmukh and Ms. Ritu Garad as Non-Executive Directors, subject to shareholder approval at an EGM on April 2, 2026.

Governance Positive

2026-03-10 15:28

Board approved proposed name change to ISERA Lifesciences Limited, shifting of registered office, and recommended the appointment of two Executive Directors (Mr. Dhairyasheel Yadav, Mr. Nandkumar Kadam) and two Non-Executive Directors. An EGM is scheduled for April 2, 2026, for shareholder approvals.

Business Update Positive

2026-02-23 20:46

Covidh Technologies Limited issued a revised disclosure correcting the name of the target entity for its proposed 100% equity acquisition. The company executed a non-binding Letter of Intent to acquire iSERA Biological Limited.

Business Update Positive

2026-02-23 19:00

Covidh Technologies Limited executed a non-binding Letter of Intent on February 23, 2026, for the proposed acquisition of 100% equity shareholding of iSERA Biological Private Limited. This would make iSERA a wholly-owned subsidiary upon completion.

Business Update Neutral

2026-02-16 15:54

Covidh Technologies Limited's Registered Office has shifted from Hyderabad, Telangana to Pune, Maharashtra, effective February 06, 2026, after receiving regulatory approval for the change of state.

Routine Positive

2026-02-14 14:51

Covidh Technologies Limited submitted the Monitoring Agency Report for the quarter ended December 31, 2025, concerning the utilization of Rights Issue proceeds. The report confirms nil deviation in the utilization of funds from the stated objects, with balance proceeds to be utilized as per the Letter of Offer.

Financials Positive

2026-02-10 16:22

Standalone Revenue ₹19.32Lakhs vs ₹19.32Lakhs (▲0% YoY). PAT loss reduced from ₹29.04Lakhs to ₹28.20Lakhs (▲2.89% YoY). EBITDA loss reduced from ₹29.29Lakhs to ₹28.45Lakhs (▲2.87% YoY). EBITDA Margin -147.26% vs -151.60% (▲434bps).

Financials Negative

2026-02-10 16:12

Standalone Total Income ₹19.57 Lakhs vs ₹20.57 Lakhs (▼4.86% YoY). Net Loss for the quarter widened to ₹28.20 Lakhs from ₹6.65 Lakhs in the prior year quarter.

Governance Positive

2026-02-09 14:49

COVIDH TECHNOLOGIES LIMITED received regulatory approval on January 09, 2026, for shifting its Registered Office from Telangana to Maharashtra. This move, approved by its Board and shareholders in Aug 2025, aims to enlarge business operations and exploit marketing opportunities. The effective date will be intimated later.

534920

COVIDH TECHNOLOGIES LTD

Filing History

Unlock Full History